Data gathered: May 19
Alternative Data for Assertio Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 89 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 16,337 | Sign up | Sign up | Sign up |
| Twitter Followers | 75 | Sign up | Sign up | Sign up |
| Twitter Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 31 | Sign up | Sign up | Sign up |
| Linkedin Employees | 48 | Sign up | Sign up | Sign up |
About Assertio Therapeutics
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system.
| Price | $1.07 |
| Target Price | Sign up |
| Volume | 552,990 |
| Market Cap | $102M |
| Year Range | $0.75 - $3.05 |
| Dividend Yield | 0% |
| Revenue per Employee | $4,625,700 |
| Industry | Biotechnology |
In the news
 |
Assertio Holdings, Inc. (NASDAQ:ASRT) Q1 2024 Earnings Call TranscriptMay 7 - Yahoo |
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)May 6 - TipRanks |
|
 |
Assertio Holdings Inc (ASRT) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ...May 6 - Yahoo |
 |
Assertio Holdings Inc (ASRT) Surpasses Revenue Estimates But Reports Wider Loss in Q1 2024May 6 - Yahoo |
 |
Assertio Holdings, Inc. (ASRT) Q1 2024 Earnings Call TranscriptMay 6 - SeekingAlpha |
ASRT Stock Earnings: Assertio Holdings Beats EPS, Beats Revenue for Q1 2024May 5 - InvestorPlace |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '23 | 32M | 82M | -49M | -57M | -26M | -0.610 |
| Q3 '23 | 35M | 280M | -245M | -280M | -218M | -0.460 |
| Q2 '23 | 40M | 28M | 12M | 8.5M | 19M | 0.130 |
| Q1 '23 | 31M | 29M | 2.8M | -3.5M | 1.8M | -0.070 |
| Q4 '22 | 50M | 28M | 22M | 89M | 18M | 1.340 |
Insider Transactions View All
| Tyree James L filed to sell 188,251 shares at $1.1. March 15 '24 |
| Peisert Daniel A. filed to sell 324,939 shares at $3. September 13 '23 |
| Patel Ajay filed to sell 93,643 shares at $3. September 13 '23 |
| Schlessinger Sam filed to sell 69,038 shares at $3. September 13 '23 |
| Peisert Daniel A. filed to sell 356,060 shares at $3. September 13 '23 |
Similar companies
Read more about Assertio Therapeutics (ASRT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Assertio Therapeutics?
The Market Cap of Assertio Therapeutics is $102M.
How Many People Work at Assertio Therapeutics?
As of our latest update, Assertio Therapeutics employed approximately 30 people worldwide. However, it's important to note that Assertio Therapeutics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.
What is Assertio Therapeutics' revenue per employee?
$4,625,700. To calculate Assertio Therapeutics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.
What is the current stock price of Assertio Therapeutics?
Currently, the price of one share of Assertio Therapeutics stock is $1.07.
How can I analyze the ASRT stock price chart for investment decisions?
The ASRT stock price chart above provides a comprehensive visual representation of Assertio Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Assertio Therapeutics shares. Our platform offers an up-to-date ASRT stock price chart, along with technical data analysis and alternative data insights.
Does ASRT offer dividends to its shareholders?
As of our latest update, Assertio Therapeutics (ASRT) does not offer dividends to its shareholders. Investors interested in Assertio Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Assertio Therapeutics?
Some of the similar stocks of Assertio Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.